Dr. Tripathy on Ixabepilone in Patients With TNBC

Debu Tripathy, MD
Published: Sunday, Mar 13, 2016



Debu Tripathy, MD, chair, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the use of ixabepilone as a treatment for patients with triple-negative breast cancer (TNBC).

Ixabepilone is an epothilone agent that was approved by the FDA for its demonstrated efficacy in patients who are refractory to taxane-based therapies, Tripathy explains. The mechanism of action of ixabepilone differs from that of a taxane; patients who are resistant to taxanes will experience membrane transport.

However, questions do remain with optimal incorporation of ixabepilone. The clinical trials that led to the approval of ixabepilone compared capecitabine with or without ixabepilone. Findings showed that disease-free survival is improved with the combination, Tripathy says.

<<< View more from the 33rd Annual Miami Breast Cancer Conference



Debu Tripathy, MD, chair, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the use of ixabepilone as a treatment for patients with triple-negative breast cancer (TNBC).

Ixabepilone is an epothilone agent that was approved by the FDA for its demonstrated efficacy in patients who are refractory to taxane-based therapies, Tripathy explains. The mechanism of action of ixabepilone differs from that of a taxane; patients who are resistant to taxanes will experience membrane transport.

However, questions do remain with optimal incorporation of ixabepilone. The clinical trials that led to the approval of ixabepilone compared capecitabine with or without ixabepilone. Findings showed that disease-free survival is improved with the combination, Tripathy says.

<<< View more from the 33rd Annual Miami Breast Cancer Conference




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x